LNA-based pan-Ras protein mRNA antagonists (Santaris)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameLNA-based pan-Ras protein mRNA antagonists (Santaris)
Drug Alias Nameanti-H-Ras (Santaris)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionGTPase Ras inhibitors
TargetsGTPase Ras
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmark
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRoche Innovation Center Copenhagen A/S
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRoche Innovation Center Copenhagen A/S
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A